Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy

NCT05858983 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Biallelic RPE65 Mutation-associated Retinal Dystrophy

Interventions

GENETIC: FT-001 Low Dose
GENETIC: FT-001 Mid Dose
GENETIC: FT-001 High Dose

Sponsor

Frontera Therapeutics